Supplementary Figure S4 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer

Figure S4. A. Heatmap of CXC chemokines ligands (CXCL) based on pretreatment bulk RNA-seq data between responders and non-responders. B. CCL5 expression in each MOC model cultured media with or without IFN-γ stimulation (100U/ml for 48 hours) were analyzed by CCL5-ELISA. n=2-3. C. p value and r squared value calculated from Pearson correlation coefficient of cDC score and chemokine RNA expression are plotted. Broken line represents a p value of 0.05. D. Number of Xcr1+ DCs migrated using the migration assay described in Methods. E. Distribution plots showing cumulative expression levels of CCL5 in various immune subtypes other than CD8+ T cells, based on scRNA-seq of HNSCC patients prior to pembrolizumab. Left panel responders, right panel non-responders. F, G. Comparison of CCL5 expression in bulk RNA-seq data from pre and post treatment samples in responders (F) and non-responders (G), shown as z-score. n=6. H. Violin plot showing CCL5 expression level in human dendritic cells between responders pre- and post-treatment based on scRNA-seq data